News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

TYRX Release: Vanderbilt Study Shows Sharp Decline in Cardiac Device Infections With TYRX® AIGISRx® Antibacterial Envelope


12/18/2012 9:25:59 AM

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Patients at high risk for surgical site infection following Cardiac Implantable Electronic Device (CIED) implantation with TYRX, Inc.’s AIGISRx Antibacterial Envelope experienced significantly reduced risk of device infection compared to patients implanted without AIGISRx. Results of a retrospective cohort study of CIED implantations, including pacemakers and implantable defibrillators, were published online in the journal of Pacing and Clinical Electrophysiology (PACE).

Read at BioSpace.com

comments powered by Disqus
TYRX
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES